注射型唑来膦酸盐治疗绝经后骨质疏松症临床观察.doc

注射型唑来膦酸盐治疗绝经后骨质疏松症临床观察[摘要] 目的 探讨唑来膦酸注射液治疗绝经后骨质疏松症的临床疗效，评价其安全性。 方法 将绝经后骨质疏松症患者70例随机分成治疗组和对照组，各35例，两组在年龄、绝经年限等方面比较差异均无统计学意义（P ＞ 0.05）。治疗组给予唑来膦酸注射液（密固达）5 mg/100 mL静滴1次，同时口服钙尔奇片。对照组仅给予口服钙尔奇片，两组受试者均连续服药10个月。观察骨痛、骨密度变化及安全性指标。 结果 治疗后治疗组骨痛症状明显缓解，两组总有效率比较差异有统计学意义（P ＜ 0.05）；骨密度检测治疗组增加与对照组比较差异有统计学意义（P ＜ 0.05）；治疗期间治疗组无新发骨折。 结论 唑来膦酸注射液对绝经后骨质疏松症患者具有缓解骨痛、增加骨密度、提高生活质量、减少骨折发生的作用，是一种有效、安全的药物。 [关键词] 唑来膦酸；骨质疏松；绝经后；骨密度 [中图分类号] R681 [文献标识码] A [文章编号] 1673-7210（2012）01（c）-0073-02 Clinical observation of Zoledronic Acid Salt Injection in the treatment of postmenopausal osteoporosis SONG Yanyun1 XIN Jian2 1.Shandong Athlete Rehabilitation Center, Shandong Province, Ji’nan 250102, China; 2.The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong Province, Ji’nan 250011, China [Abstract] Objective To explore the clinical efficacy of Zoledronic Acid Injection in the treatment of postmenopausal osteoporosis and to assess its safety. Methods 70 patients with postmenopausal osteoporosis were randomly divided into treatment group and control group, with 35 cases in each group and no significant differences in age, menopause and so on (P ＞ 0.05). For the treatment group, 5 mg/100 mL of Zoledronic Acid Injection (Aclasta) was infused once while Caltrate was taken orally. For the control group, only Caltrate was taken orally. Subjects of the two groups took medicine for 10 consecutive months. Then bone pain, bone mineral density (BMD) variance and safety indicators were observed. Results After treatment, the bone pain of the treatment group was mitigated greatly, the difference of the total effective rate between the two groups was significant (P ＜ 0.05); the BMD increase was significant compared with that of the control group (P ＜ 0.05); during the treatment, no new fractures occurred in the treatment group. Conclusion Zoledronic Acid Injection can ease the bone pain of postmenopausal osteoporosis, improve life quality, increase BMD and reduce the occ